Please login to the form below

Not currently logged in

FDA set to publish reviews of data relating to COVID-19 vaccine EUAs

Agency set to publish data as part of 'transparency' efforts

The US Food and Drug Administration (FDA) has announced that it will publicly post reviews of data relating to emergency use authorisations (EUA) of COVID-19 vaccines.

In a statement, FDA commissioner Stephen Hahn revealed the transparency plans, adding that the agency’s drug and biological products center will publish its reviews ‘to the extent appropriate and permitted by law’.

“Let me be clear on a crucial point – the issuance of an EUA is based on data and science. For an EUA to be authorised, FDA’s career scientists conduct a rigorous evaluation of currently available scientific evidence about a medical product,” said Hahn

“We work with sponsors so that additional data about the product’s safety and effectiveness continues to be collected and reviewed,” he added.

In October, the FDA released new guidelines detailing how it will grant EUAs for COVID-19 vaccines, which included a new advisory stipulating that data from phase 3 studies should include a median follow-up duration of at least two months.

Following this guidance, Bloomberg reported that the FDA will also not require pre-approval inspections for vaccine developers seeking EUAs.

Jerry Weir, director of viral products at the FDA’s vaccines office, revealed that companies who submit their COVID-19 vaccine for an EUA will not have to undergo these inspections during an FDA advisory committee meeting.

Weir did add that all companies that submit a potential COVID-19 vaccine for an EUA will be required to provide complete details of their manufacturing processes and demonstrate how they have established a quality control unit.

A number of potential vaccines are involved in late-stage clinical testing, and Pfizer/BioNTech and Moderna have both reported initial efficacy data on their vaccine candidates this month.

Pfizer/BioNTech’s COVID-19 vaccine candidate, BNT162b2, demonstrated an efficacy rate of above 90% in preliminary results from a phase 3 study that was published last week.

On Monday, Moderna also revealed the first results for its vaccine, mRNA-1273, reporting that the vaccine candidate achieved an efficacy rate of 94.5% in its phase 3 study.

The respective vaccine developers did add, however, that this efficacy rate could change over the course of ongoing evaluations.

Article by
Lucy Parsons

18th November 2020

From: Regulatory



Subscribe to our email news alerts


Add my company
Springer Nature

Operating in 50+ countries, we’re a leading research, educational, and professional publisher dedicated to advancing scientific discovery. Whether you’re looking...

Latest intelligence

Improving cardiovascular disease care and awareness
Scott Curley talks to PME about the risks of CVD and the importance of getting the right treatment at the right time...
Virtual Patient Engagement Program: A Customer Story
Our client wanted to better understand the needs, preferences, and treatment gaps among adult patients with a rare genetic disease......
Humancomms for humancare?
Paul Hutchings, founder of fox&cat, writes on the role of humour in healthcare comms: PharmaComms 2023...